Insider filing · NAMS
Michael H. Davidson
Chief Executive Officer
profile →
NewAmsterdam Pharma Company N.V.
NAMS · Healthcare · 45 filings in 24 months
ticker →
Michael H. Davidson sold $411K of NewAmsterdam Pharma (NAMS)
Executed Jan 7, disclosed Jan 9, 2 days later.
Value, as filed
$411K
as filed
Executed
Jan 7
the trade date, as filed
Disclosed
Jan 9
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
MDMichael H. Davidson (Chief Executive Officer) filed 4 Form 4 reports in the trailing twelve months (1 purchase, 3 sales), most often in NewAmsterdam Pharma Company N.V. (NAMS). The largest single filing was $14.8M of NAMS (443,707 sh × $33.25, as filed), executed Mar 2. The median gap between execution and disclosure was 1 day.
The name
NAMSHealthcare · NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with ca…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Michael H. Davidson in NAMS
NAMSPURCHASE
NewAmsterdam Pharma Company N.V.
$226K10,000 sh × $22.65
Exec Sep 14
Filed Sep 15 · 4:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $14.8M
443,707 sh × $33.25
Exec Mar 2
Filed Mar 2 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $10.5M
304,993 sh across 6 lots
Exec Feb 24
Filed Feb 26 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $277K
as filed
Exec Mar 26 2025
Filed Mar 28 2025 · 5:30 PM ET